Applying the WHO ICF framework to long COVID patients with persistent respiratory symptoms.

Objectives: The aim of this study was to evaluate long COVID patients with persistent respiratory symptoms through the application of the World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) framework. Patients and methods: This national, prospective, multicenter, cross-sectional study was conducted with 213 patients (118 females, 95 males; median age 56 years; range, 20 to 85 years) with long COVID between February 2022 and November 2022. The ICF data were primarily collected through patient interviews and from the acute medical management records, physical examination findings, rehabilitation outcomes, and laboratory test results. Each parameter was linked to the Component Body Functions (CBF), the Component Body Structures (CBS), the Component Activities and Participation (CAP), the Component Environmental Factors (CEF), and Personal Factors according to the ICF linking rules. Analysis was made of the frequency of the problems encountered at each level of ICF category and by what percentage of the patient sample. Results: In the ICF, 21 categories for CBF, 1 category for CBS, and 18 categories of CAP were reported as a significant problem in a Turkish population of long COVID patients with persistent respiratory symptoms. Furthermore, eight categories for CEF were described as a facilitator, and four as a barrier. Conclusion: These results can be of guidance and provide insight into the identification of health and health-related conditions of long COVID patients with persistent respiratory symptoms beyond the pathophysiological aspects, organ involvement, and damage of COVID-19. The ICF can be used in patients with long COVID to describe the types and magnitude of impairments, restrictions, special needs, and complications.

COVID-19, cardiac involvement and cardiac rehabilitation: Insights from a rehabilitation perspective - State of the Art.

Since the beginning of the pandemic, many novel coronavirus disease 2019 (COVID-19) patients have experienced multisystem involvement or become critically ill and treated in intensive care units, and even died. Among these systemic effects, cardiac involvement may have very important consequences for the patient's prognosis and later life. Patients with COVID-19 may develop cardiac complications such as heart failure, myocarditis, pericarditis, vasculitis, acute coronary syndrome, and cardiac arrhythmias or trigger an accompanying cardiac disease. The ratio of COVID-19 cardiac involvement ranges between 7 and 28% in hospitalized patients with worse outcomes, longer stay in the intensive care unit, and a higher risk of death. Furthermore, deconditioning due to immobility and muscle involvement can be seen in post-COVID-19 patients and significant physical, cognitive and psychosocial impairments may be observed in some cases. Considering that the definition of health is "a state of complete physical, mental and social well-being", individuals with heart involvement due to COVID-19 should be rehabilitated by evaluating all these aspects of the disease effect. In the light of the rehabilitation perspective and given the increasing number of patients with cardiac manifestations of COVID-19, in this review, we discuss the rehabilitation principles in this group of patients.

Comparison of Effects of Leukocyte-Rich and Leukocyte-Poor Platelet-Rich Plasma on Pain and Functionality in Patients With Lateral Epicondylitis.

OBJECTIVES: This study aims to compare the effect of leukocyte concentration in platelet-rich plasma (PRP) on pain, functionality and post-injection local inflammatory reactions in patients with lateral epicondylitis. PATIENTS AND METHODS: The study included 90 patients (26 males, 64 females; mean age 38.6 years; range 18 to 75 years) with lateral epicondylitis- related pain visual analog scale (VAS) score of ≥5 for more than three months. Patients were randomly assigned into three groups. Normal saline (1.5 mL) was injected in group 1 (control group) while a single dose of leukocyte-poor-PRP (1.5 mL) and leukocyte-rich-PRP (1.5 mL) were injected in groups 2 and 3, respectively. An exercise program was recommended to patients in all three groups. Patients were assessed according to VAS, Patient-Rated Tennis Elbow Evaluation, grip dynamometer and pinchmeter, extensor tendon thickness and cortical derangement at baseline and at fourth and eighth weeks after therapy. All patients were questioned regarding paracetamol use and adverse effects after therapy. RESULTS: No significant differences were detected between groups regarding VAS, Patient-Rated Tennis Elbow Evaluation, grip and pinch measurements, extensor tendon thickness and cortical derangement (p>0.05). In intra-group comparisons, VAS and Patient-Rated Tennis Elbow Evaluation scores obtained at fourth and eighth weeks were significantly decreased in all groups when compared to baseline values (p>0.05). Again, there was no significant difference in the control visit at eighth week when compared to baseline. Assessment of grip and pinch measurements revealed that values obtained at fourth and eighth weeks were significantly increased compared to baseline in all three groups (p<0.05). In leukocyte-rich-PRP group, a significant increase was detected in the values obtained at eighth week compared to those obtained at fourth week, but no significant change was detected in other groups. No significant difference was detected in extensor tendon thickness in any group. No significant difference was detected between groups in terms of paracetamol use and post-injection reactions. CONCLUSION: According to our study findings, lateral epicondylitis does not seem to affected either leukocyte-rich-PRP or leukocyte-poor-PRP on pain and function in the short term. Leukocyte concentration had no association with post-injection local inflammatory reactions.

Comparison of the short-term effects of the conventional motorized traction with non-surgical spinal decompression performed with a DRX9000 device on pain, functionality, depression, and quality of life in patients with low back pain associated with lumbar disc herniation: A single-blind randomized-controlled trial.

OBJECTIVES: This study aims to compare the efficiency of conventional motorized traction (CMT) with non-surgical spinal decompression (NSD) using the DRX9000™ device in patients with low back pain associated with lumbar disc herniation (LDH). PATIENTS AND METHODS: Between March 2009 and September 2009, a total of 48 patients (29 females, 19 males; mean age 43.1±9.8 years; range, 18 to 65 years) were randomized into two groups. The first group (n=24) underwent CMT and the second group (n=24) underwent NSD for a total of 20 sessions over six weeks. The patients were evaluated before and after the treatment. Pain was assessed using the Visual Analog Scale (VAS), functional status using the Oswestry Disability Index (ODI), quality of life using the Short Form-36 (SF-36), state of depression mood using the Beck Depression Inventory (BDI), and the global assessment of the illness using the Patient's Global Assessment of Response to Therapy (PGART) and Investigator's Global Assessment of Response to Therapy (IGART) scales. RESULTS: There was no significant difference in the evaluation outcomes before the treatment between the groups. However, a statistically significant decline was found in the VAS, ODI, and BDI scores after the treatment in both groups (all p<0.001). Except for two subgroups, no significant changes were observed in the SF-36 form. Assessment of "marked improvement" was globally most frequently reported one in both groups. No significant difference was observed in the evaluation outcomes after treatment between the groups. CONCLUSION: Our study results show that both CMT and NSD are effective methods in pain management and functional status and depressive mood improvement in patients with LDH, and NSD is not superior to CMT in terms of pain, functionality, depression and quality of life.